Researchers link global increase in type 1 diabetes to advances in medical care

Researchers from the University of Adelaide say the global increase in cases of type 1 diabetes is directly linked to advances in medical care, with the underlying genetics of the disease more likely to be passed from one generation to the next.

In a paper published in BMJ Open Diabetes Research & Care, researchers looked at the prevalence of type 1 diabetes in 118 countries and changes in life expectancy from 1950 to 2010.

After applying a measure known as the Biological State Index to the data, they found that the rapid increase in type 1 diabetes over the last few decades was directly linked with increases in human life expectancy, especially in Western countries - and therefore a reduction in natural selection.

"Up to the early 20th century, type 1 diabetes was a horrible and dangerous disease, usually leading to people's death during their teens or early 20s," says lead author Wenpeng You, PhD student in the University of Adelaide's Biological Anthropology and Comparative Anatomy Research Unit, School of Medicine.

"This meant there was limited opportunity for people with the disease to have children and to pass their genetic material onto future generations. In evolutionary terms, this is what we call 'natural selection'.

"However, with the widespread introduction of insulin from the 1920s onwards, and improvements in modern medicine, life expectancy for people with type 1 diabetes has now increased to about 69 years.

"That is a remarkable achievement, but it also means that with reduced natural selection, the genetic material leading to the development of type 1 diabetes may be accumulating at a rapid rate within the world's population," Mr You says.

The researchers decided to investigate the link because although cases of type 1 diabetes have been increasing globally, its prevalence is uneven in different parts of the world.

"Not every country has access to good health care, or freely available insulin. In a number of poor countries, such as in Africa, the life expectancy for people with type 1 diabetes is much lower than in the Western world. This means more people are dying prematurely, with less opportunity to produce offspring who will carry those genes from generation to generation," Mr You says.

Supervisor and co-author Professor Maciej Henneberg says: "Natural selection is one of the major evolutionary forces that inform changes in our genes, across populations and over generations.

"This is the first major disease we have shown that is accumulating due to a relaxation of natural selection over time. It's unlikely this situation will ever be reversed, meaning that in order to overcome the problems associated with type 1 diabetes for our population, some form of gene therapy to repair the faulty genes may need to be considered," he says.

Comments

  1. Stuart Evans Stuart Evans Australia says:

    The practise of human medicine has been weakening the human genome in this manner ever since the days of witchdoctors.  Think of midwifery advances allowing women with smaller hips to give birth successfully, let alone the abortion of male foetuses in families plagued with haemophilia.  Modification of germline genetics, (crispr-cas9) could prevent this deterioration, but would any democracy have the ability to do so?

  2. Stuart Evans Stuart Evans Australia says:

    The practise of medicine has been weakening the human genome since the days of witchcoctors.  Think of advances in midwifery leading to women with smaller hips and birth canals, let alone the abortion of male foetuses in families plagued with haemophilia.  Modification of germline genetics (crispr-cas9) could prevent this deterioration, but would any democracy have the ability to do so?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes drug semaglutide proves beneficial for patients with chronic kidney damage and obesity